Paratek Pharmaceuticals, Inc. (PRTK) News

Paratek Pharmaceuticals, Inc. (PRTK): $5.15

-0.14 (-2.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRTK to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

Filter PRTK News Items

PRTK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PRTK News Highlights

  • For PRTK, its 30 day story count is now at 6.
  • Over the past 23 days, the trend for PRTK's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about PRTK are SKIN.

Latest PRTK News From Around the Web

Below are the latest news stories about Paratek Pharmaceuticals Inc that investors may wish to consider to help them evaluate PRTK as an investment opportunity.

Bret Jensen: Paratek Deal Shows Promise

While antibiotics are usually less profitable and slower to develop market share than other drugs, Paratek has a key factor in its favor.

Yahoo | September 24, 2021

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021

Key highlights include real-world health outcomes data for pneumonia and skin infections, data on in vitro activity against B. anthracis, and real-world experience for nontuberculous mycobacterial infectionsBOSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that data from the NUZYRA® (omadacycline) clinical and microbiology programs are being presented at the IDWeek 2021 virtual meeting. Poster presentations will be available beginning on Wedn

Yahoo | September 23, 2021

Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Randy Brenner, Chief Development and Regulatory Officer, will present at the H.C. Wainwright 23 rd Annual Global Investment (Virtual) Conference. The on-demand presentation will be available on September 13 at 7:00 a.m. ET.

Intrado Digital Media | September 9, 2021

Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Randy Brenner, Chief Development and Regulatory Officer, will present at the H.C. Wainwright 23rd Annual Global Investment (Virtual) Conference. The on-demand pr

Yahoo | September 9, 2021

Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM

The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.

Yahoo | August 19, 2021

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV) Alkermes plc (NASDAQ: ALKS) Bio-Rad Laboratories, Inc. (NYSE: BIO) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) Gilead Sciences, Inc. (NASDAQ: GILD) GlaxoSmithKline plc (NYSE: GSK) (announced FDA approval for label expansion for its Jemperli) Novo Nordisk A/S (NYSE: NVO) Innoviva, Inc. (NASDAQ: INVA) Intuitive Surgical, Inc.

Yahoo | August 19, 2021

Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection

The FDA has granted Orphan Drug Designation to Paratek Pharmaceuticals Inc's (NASDAQ: PRTK), Nuzyra (omadacycline) for infections caused by Nontuberculous Mycobacteria (NTM). The orphan drug designation includes NTM pulmonary disease caused by Mycobacterium abscessus complex (MABc), currently in an ongoing Phase 2b study initiated by Paratek. Nuzyra is a once-daily, broad-spectrum antibiotic currently approved for acute bacterial skin and skin structure infections and community-acquired bacteria

Yahoo | August 19, 2021

Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA® (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria

BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for NUZYRA ® (omadacycline) for the treatment of infections caused by Nontuberculous Mycobacteria (NTM). This orphan drug designation includes NTM pulmonary disease caused by Mycobacterium abscessus complex (MABc), which is the focus of an ongoing Phase 2b study initiated by Paratek. The FDAs Office of Orphan Drug Products grants orphan status to drugs and biologic...

Intrado Digital Media | August 18, 2021

What Percentage Of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Shares Do Insiders Own?

The big shareholder groups in Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) have power over the company. Large...

Yahoo | August 10, 2021

Paratek Pharmaceuticals (PRTK) Q2 2021 Earnings Call Transcript

Thank you, operator, and good afternoon, everyone, and welcome to Paratek's second-quarter 2021 earnings and corporate update conference call. Participants on today's call are Evan Loh, chief executive officer; Adam Woodrow, president and chief commercial officer; and Randy Brenner, chief development and regulatory officer.

Yahoo | August 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8588 seconds.